Clinical Research Directory
Browse clinical research sites, groups, and studies.
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Sponsor: Indapta Therapeutics, INC.
Summary
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Official title: Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2023-10-25
Completion Date
2029-12-31
Last Updated
2025-06-03
Healthy Volunteers
No
Conditions
Interventions
IDP-023
NK cell therapy
Rituximab
Anti-CD20 antibody therapy
Daratumumab
Anti-CD38 antibody therapy
Interleukin-2
Immune cytokine
Cyclophosphamide
Lymphodepleting chemotherapy
Fludarabine
Lymphodepleting chemotherapy
Mesna
Chemoprotectant
Isatuximab
Anti-CD38 antibody therapy
Locations (12)
Valkyrie Clinical Trials
Los Angeles, California, United States
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center
Lake Mary, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
University of Minnesota
Minneapolis, Minnesota, United States
NYP/Weill Cornell Medical Center
New York, New York, United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
University Hospitals Cleveland
Cleveland, Ohio, United States
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States
Rhode Island Hospital
Providence, Rhode Island, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology Virginia
Fairfax, Virginia, United States